SafePolyMed

Improve Safety in Polymedication by Managing Drug-Drug-Gene Interactions


Description

Polypharmacy, multimorbidity and genetic heterogeneity can affect drug efficacy, raise the risk for adverse drug reactions (ADRs) and increase healthcare costs. ADRs are among the leading causes of death in developed countries and a major cause of hospitalization. Drug-drug interactions (DDIs) and drug-gene interactions (DGIs) are highly interconnected and require a holistic approach to improve safety of our citizens. However, investigations on real-life drug-drug-gene interactions (DDGIs) in clinical trials are unfeasible due to combinatorial explosion, high costs and ethical concerns. Hence, significant knowledge gaps exist. Furthermore, the lack of participation in managing their conditions might be excessively demanding for polymedicated and multimorbid citizens.

Bringing together 12 partners from across Europe, SafePolyMed will develop a novel and innovative framework to define, assess and manage DDGIs for physicians and individual patients resulting in education and empowerment of citizens as well as in reduced healthcare costs by improving patient safety.

Coordinator
Prof. Dr Thorsten Lehr
Universität des Saarlandes
Phone: +49 681 302 70255
Programme
Horizon Europe & sub-programmes
Duration
42 months (July 2022 - December 2025)
Project funding
€ 5,650,442.81
Project partners
12
Project website
https://www.safepolymed.eu/
Download Factsheet
Your contact
Klara Schneider
Project Manager
Phone: +49 6894 3881313
E-mail
About Eurice

Eurice offers knowledge-based consultancy services in project and innovation management.

Eurice Head Office
Heinrich-Hertz-Allee 1
66386 St. Ingbert
Germany
Phone: +49 6894 388130
Email
Eurice Berlin
Alt-Reinickendorf 25
13407 Berlin
Germany
Phone: +49 30 374415840
Email